Research programme: spinal muscular atrophy therapeutics - Roche
Alternative Names: Spinal muscular atrophy therapeutics - RocheLatest Information Update: 04 Feb 2021
At a glance
- Originator Roche
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Spinal muscular atrophy